GW Pharmaceuticals tests epilepsy drug in man as FDA softens stance

A.B. | ShareCast | 18 Sep, 2013 11:09 - Updated: 11:59 | | |


Cannabis-derived drug developer GW Pharmaceuticals has begun human trials of its epilepsy treatment.

The AIM- and Nasdaq-listed company said the novel drug candidate, currently named GWP42006, was one of its most promising and looked to have significantly fewer side effects than currently approved anti-epileptic drugs.

Dr. Stephen Wright, Director of Research and Development at the company said advancing GWP42006 to a first dose in man was a significant milestone in the development of this candidate.

“The decision to progress into Phase 1 follows several years of highly promising pre-clinical research," he added.

"We believe that GWP42006 has the potential to become an important advance in the treatment of epilepsy, a condition for which there remains a substantial unmet medical need."

Research with the Reading School of Pharmacy in Buckinghamshire has shown that GWP42006 not only exerts significant ability to treat seizures in a wide range of preclinical models of seizure and epilepsy, but is also better tolerated by patients compared to existing anti-epileptic drugs.

The company has been encouraged by recent interest in its products in the US. That arose after the pharmaceutical regulator, the Food and Drug Administration [FDA], allowed US epilepsy specialists and patient organizations to carry out treatment on a small number of pediatric epilepsy patients with a cannabidiol [CBD] formulation supplied by GW. These activities may generate initial evidence to add CBD as a further pipeline candidate for clinical evaluation in epilepsy.

Recent third quarter showed net cash of $66.3m thanks to a US IPO in May that raised $30.4m.

Shares in GWP were up 1.4% to 72p at 11:12 on Wednesday.


More news

09:00 Tesco execs in South Korea could face prosecution in latest scandal development

South Korean Tesco executives will potentially be prosecuted over claims the company sold customer data without obtaining proper permissions.

08:58 President Energy shares rocket after oil discovery in Paraguay

President Energy has made its first-ever oil discovery at its majority-owned Pirity concession in the Paraguayan Chaco region, causing shares to rocket on Monday.

08:56 Market overview: Tesco advances, Daisy Group surges

0846: UK stocks have started week with slight losses, although Tesco is moving higher. Reports over the weekend indicated that the grocer’s misreporting of profits was largely limited to the first half of this past year. Daisy Group is an outstanding performer early on after the announcement of a management buy-out. Market commentary this morning seems to be highlighting France’s upcoming budget battles, as well as next weekend’s ECB stress test results. Traders are also expectant ahead of tonight’s results out of tech giant Apple. FTSE 100 down 18 points to 6,294.

08:37 FX round-up: US dollar gains on positive data, central bankers' remarks

The last session of the previous week saw risk appetite recover further on the back of better-than-expected economic data Stateside.

08:15 Close Brothers sells German securities business for £36m

Close Brothers has sold its German securities business, Close Brothers Seydler Bank, for a cash consideration of £36m.

08:12 Economic policy concerns for Japan as two controversial ministers resign on same day

Two of Japan’s female ministers stepped down on Monday, breaking a nearly two-year run without any resignations from Japanese prime minister Shinzo Abe’s cabinet.

08:11 Support and resistance levels for the main currency pairs

The following are the technical support and resistance levels for Forex trading.

08:10 McBride makes solid start to year

Consumer goods maker McBride hailed a solid start to the year and said it was trading in line with hopes.

07:58 Daisy Group recommends £494m offer from CEO-led consortium

AIM-listed telecoms company Daisy Group has reached an agreement on a recommended cash offer of just under half a billion pounds from a consortium of investors including its boss Matthew Riley.

07:45 Spirit gets fresh takeover offer from Greene King

Pub group Spirit has received a fresh takeover offer from rival Greene King at about 109.5p per share. Spirit has told Greene King it would recommend the offer subject to approval of other terms and is in talks with them.



Ebola latest: Spanish nurse tests negative for virus for first time

Welcome to our rolling coverage of the Ebola crisis.


EUR/USD: continues its clearly bearish trend